Among them, MET is of particular interest because recent clinical trials demonstrated that MET inhibitors had significant clinical activity [8, 9], particularly in patients whose tumors contained MET amplification [10–12], and preclinical studies indicated that MET amplification usually created MET dependency in gastric cancer cells [13, 14]. The gene discussed is MET; the disease is gastric cancer.